Literature DB >> 8235490

Serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and systemic idiopathic vasculitis.

M G Danieli1, P Paoletti, A Recchioni, A Gabrielli, G Danieli.   

Abstract

Soluble interleukin 2 receptor (sIL2R) may be used as an index of immune perturbation. We report on the correlation between the serum levels of sIL2R, as assessed with a sandwich-ELISA, and disease activity in 61 patients with Systemic Lupus Erythematosus (SLE) and in 15 with systemic idiopathic vasculitis (SIV). The mean levels of sIL2R in SLE and SIV patients were significantly higher than in healthy controls and higher values were detected in patients with active disease or severe organ involvement or infection. We also studied patients with clinically silent SLE, characterized by the presence of several immunologic abnormalities. The sIL2R mean level in this group did not differ from that of quiescent SLE patients, suggesting that immunologic alterations are present even in inactive SLE. Finally, the sIL2R assay showed higher sensitivity and specificity than most of the common immunologic parameters.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235490     DOI: 10.3109/03009749309095125

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  2 in total

1.  HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus.

Authors:  J F Viallard; C Bloch-Michel; M Neau-Cransac; J L Taupin; S Garrigue; V Miossec; P Mercie; J L Pellegrin; J F Moreau
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  Serial monitoring of interleukin-1beta, soluble interleukin-2 receptor and lipopolysaccharide binding protein levels after death A comparative evaluation of potential postmortem markers of sepsis.

Authors:  Uta Reichelt; Roman Jung; Axel Nierhaus; Michael Tsokos
Journal:  Int J Legal Med       Date:  2004-09-04       Impact factor: 2.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.